A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer  by Ma, Wen Wee et al.
A Tolerability and
Pharmacokinetic Study




Wen Wee Ma*, Joseph M. Herman*,
Antonio Jimeno*, Daniel Laheru*,
Wells A. Messersmith†, Christopher L. Wolfgang*,
John L. Cameron*, Timothy M. Pawlik*,
Ross C. Donehower*, Michelle A. Rudek*
and Manuel Hidalgo*,‡
*Sidney Kimmel Comprehensive Cancer Center, Johns
Hopkins University, Baltimore, MD, USA; †University of
Colorado Cancer Center, Aurora, CO, USA; ‡Centro Integral
Oncologico “Clara Campal,” Facultad de Medicina CEU
Universidad San Pablo, Centro Nacional de Investigaciones
Oncologicas, Madrid, Spain
Abstract
BACKGROUND: Erlotinib is approved for the treatment of advanced pancreas cancer. We conducted a prospective
trial to determine the safety profile and recommended phase 2 dose of erlotinib and capecitabine given concurrently
with intensity-modulated radiation therapy (IMRT) in resected pancreatic cancer patients. The pharmacokinetic profile
of this combination was also evaluated. METHODS: Patients with resected pancreatic adenocarcinoma received
erlotinib and capecitabine concurrently with IMRT delivered at 1.8 Gy daily in 28 fractions (total = 50.4 Gy). The start-
ing dose level (DL 1)was erlotinib 150mgdaily and capecitabine 800mg/m2 twice dailywithout interruption. The next
lower dose level (DL −1) was erlotinib 100 mg daily and capecitabine 800 mg/m2 twice daily (Monday to Friday).
Plasma samples were obtained for pharmacokinetic analysis. RESULTS: Thirteen patients were enrolled in total. At
DL 1, six of the seven treated patientswere evaluable for toxicities. Four completed planned treatment, but all required
treatment interruption or dose reduction. The dose-limiting toxicities were neutropenia, diarrhea, and rash. Six patients
were subsequently enrolled to and completed planned treatment in DL−1. Themost common toxicities were fatigue,
elevated liver enzymes, and anorexia. The pharmacokinetic parameters of erlotinib and OSI-420 were not significantly
different in the presence or absence of capecitabine and were consistent with historical controls. CONCLUSIONS:
When administered concurrently with IMRT, erlotinib 100 mg daily and capecitabine 800 mg/m2 twice daily (Monday
to Friday) can be administered safely in resected pancreas cancer patients, and is the recommended regimen for ef-
ficacy studies using this regimen.
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Introduction
Pancreatic adenocarcinoma is the fourth leading cause of cancer death in
the United States [1]. The current standard adjuvant treatment of pan-
creatic cancer in the United States is based on the Radiation Therapy
Oncology Group 97-04 trial. This trial included systemic gemcitabine
pre/post 5-fluorouracil (5-FU)–based chemoradiation [2].However, the
prognosis of pancreatic cancer patients after surgical resection remains
poor. The 5-year overall survival rate after pancreaticoduodenectomy
ranges from 10% to 30%, and more than 70% of patients recur after re-
section despite adjuvant therapy [3]. There is, therefore, a need for novel
chemoradiation approaches to improve the clinical outcome.
Historically, continuous infusion 5-FU has been combined with
radiation in the adjuvant setting. Capecitabine has increasingly be-
come the radiosensitizer of choice in pancreatic cancer treatment;
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however, there are limited data as to how it should be optimally com-
bined with radiation and other targeted agents [4]. Capecitabine is a
fluorouracil prodrug that is rapidly absorbed through the gastroin-
testinal tract followed by an efficient hepatic conversion to two main
metabolites: 5′-deoxy-5-fluorocytidine (5′DFCR) and 5′-deoxy-
5-fluorouridine (5′DFUR) [5,6]. 5′DFUR is hydrolyzed to 5-FU,
active metabolite of capecitabine, by thymidine phosphorylase
(TP). The tumor-specific localization of TP increases intratumoral
concentration of 5-FU during capecitabine treatment while minimizing
systemic toxicities [7]. Furthermore, radiation increases TPexpression in
tumors and concurrent capecitabine and radiation achieved synergistic
antitumor effects in a pancreatic cancer xenograft model [8–10].
The epidermal growth factor receptor (EGFR) is implicated in the
pathogenesis of many solid malignancies and is overexpressed in pan-
creatic cancer [11–13]. Erlotinib (Tarceva; OSI Pharmaceuticals, Mel-
ville, NY) is an orally available inhibitor of EGFR tyrosine kinase that
showed a small but significant survival benefit when combined with
gemcitabine in advanced pancreatic cancer patients [14]. EGFR inhibi-
tors also increase tumor TP expression and enhance the antitumor effect
of radiation in preclinical tumor models [15,16]. Erlotinib undergoes
predominantly hepatic metabolism by the cytochrome P450 CYP3A4
enzyme to an O-demethylated active metabolite (OSI-420) [17]. As
such, the coadministration of CYP3A4 modulators is expected to alter
the pharmacokinetic profile of erlotinib and its metabolites [18].
The synergistic interaction between erlotinib and capecitabine with
concurrent radiation observed in preclinical studies provides a strong
rationale to explore this multimodality treatment clinically. The devel-
opment of a safe regimen, which allows for the addition of an EGFR
inhibitor (erlotinib) to 5-FU–based chemoradiation, may result in im-
proved local and systemic tumor control. However, several studies to
date that combined EGFR inhibitors with concurrent radiation and
cytotoxic chemotherapy reported significant toxicity and the optimal
approach for phases 2 and 3 development, especially in adjuvant treat-
ment, remains to be defined [19–21]. In the current study, we report
phase 1 data aimed at determining the optimal dosing schedule, toxicity,
and pharmacokinetic profile of erlotinib and capecitabine with concur-
rent intensity-modulated radiation therapy (IMRT) in pancreatic cancer
patients after surgical resection. The study also compares the pharmaco-
kinetic profiles of capecitabine, erlotinib, and metabolites from this
study to historical controls.
Materials and Methods
Eligibility
Patients with resected, histologically confirmed pancreatic ductal
adenocarcinoma who had not previously received adjuvant or neo-
adjuvant therapy were eligible for this study. Eligibility criteria also
included age 18 years or older, EasternCooperativeOncologyGroup per-
formance status of 0 or 1, and adequate organ function, including bone
marrow (absolute neutrophil count ≥ 1500/μl, hemoglobin ≥ 9 g/dl,
platelets ≥ 100,000/μl), liver (total bilirubin ≤ 2 mg/dl, aspartate
aminotransferase/alanine aminotransferase < 5× upper limit of refer-
ence range, prothrombin time < 2 seconds more than upper limit of
reference range, activated partial thromboplastin time < 40 seconds),
and kidney (serum creatinine ≤ 2 mg/dl). Exclusion criteria included
any metastasis, other malignancies diagnosed within 5 years, previous
abdominal radiation, incomplete healing from previous oncological or
other major surgery, inability to take oral medication, pregnancy, clin-
ically active interstitial lung disease, uncontrolledmedical illnesses, and
hypersensitivity to erlotinib or capecitabine. The study protocol was
approved by the institutional review board at Johns Hopkins, and
patients were required to provide written informed consent before
study enrollment.
Treatment Plan
The primary objective of this phase 1 study was to determine the
recommended phase 2 dose for the combination of erlotinib and
capecitabine when administered concurrently with IMRTas adjuvant
therapy in resected pancreatic cancer patients. The secondary objec-
tives were to determine the toxicity and pharmacokinetic profile of
erlotinib and capecitabine when administered with IMRT. Adjuvant
treatment was initiated 6 to 8 weeks after surgery. After completion
of chemoradiation, enrolled patients began four cycles of systemic
therapy consisting of concurrent gemcitabine and elotinib after 4 to
8 weeks of rest.
The original plan was to enroll a cohort of six patients to receive adju-
vant treatment with concurrent erlotinib 150mg once daily, capecitabine
800 mg/m2 twice a day (total 1600 mg/m2 a day), and IMRTat doses
of 50.4 Gy in 28 fractions for 5.5 weeks (Table 1). On the basis of our
own institutional experience, IMRT resulted in less gastrointestinal
toxicity than three-dimensional conformal RT, and we therefore opted
to use IMRTas part of the protocol. After pancreaticoduodenectomy,
patients received 45Gy to the tumor bed (as defined from preoperative
imaging and clips) and adjacent lymph nodes as described previously
[22]. This was denoted planning treatment volume one (PTV1). The
final cone down volume PTV2 (tumor bed plus 1-1.5 cm) received an
additional 5.4Gy. After a distal or total pancreatectomy, again the tumor
bed and adjacent lymph nodes received 45 Gy to PTV1 with a cone
down (5.4 Gy) to the tumor bed alone plus 1 to 1.5 cm (PTV2).
Dose-limiting structures included the liver 50% with less than 30 Gy,
66.67% of one kidney with less than 18 Gy, and spinal cord with less
than 45 Gy, and every effort was made to limit radiation dose to the
small bowel and stomach. The goal was to ensure that the PTVwas cov-
ered by the 95% isodose line and avoid any hot spots greater than 10%
of the prescribed dose. A preplanned analysis of the first cohort was per-
formed before proceeding to complete enrollment for the phase 2 por-
tion. A dose level would be considered intolerable if 33.33% of patients
experience dose-limiting toxicity. During the analysis, the starting dose
level (dose level 1) was determined to be intolerable by this defini-
tion. The doses were modified to erlotinib 100 mg daily, capecitabine
800 mg/m2 twice daily (Monday to Friday, thereby providing a break
during weekends) to 50.4 Gy in 28 fractions (dose level −1).
Toxicity Assessment
Toxicity was assessed weekly during chemoradiation and for up to
8 weeks after the completion of chemoradiation or the start of systemic
adjuvant chemotherapy, whichever came first, using National Cancer





1 150 800 mg/m2 twice daily 5040
−1 100 800 mg/m2 twice daily
(Mon. to Fri.); Rest (Sat, Sun)
5040
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Institute Common Terminology Criteria for Adverse Events version 3.
Dose-limiting toxicity was defined as treatment-related grade 3 non-
hematological toxicity or worse despite maximal supportive treatment,
grade 4 neutropenia for 5 days or longer, grade 3 or 4 febrile neutro-
penia (absolute neutrophil count < 1.0 × 109), fever with a temperature
of 38.5°C or higher, grade 4 thrombocytopenia (<25,000/mm3), and
grade 3 or worse cutaneous toxicity. The recommended phase 2 dose
was defined as the dose level at which fewer than 2 patients of six
experience treatment-related dose-limiting toxicity.
Pharmacokinetic (PK) Sampling and Data Analysis
Pharmacokinetic (PK) studies were performed after a single dose
administration of capecitabine and erlotinib during cycle 1 day 1. Se-
rial sampling of venous blood for PK assessment was performed be-
fore and after treatment at 24 hours for erlotinib and at 8 hours for
capecitabine during cycle 1 day 1. Blood samples were processed by
centrifugation at 1000g at 4°C for 10 minutes. For capecitabine sam-
ples, tetrahydrouridine, a cytidine deaminase inhibitor, was added at a
final concentration of 400 nM to increase the stability of capecitabine
and metabolites in plasma during storage [23–25]. Plasma samples
were stored at −20°C or below until analysis.
Erlotinib and the OSI-420 metabolite and capecitabine and the 5′
DFCR, 5′DFUR, and 5-FUmetabolites were quantified using a validated
liquid chromatography–tandem mass spectrometry analytical method
[23,26]. Individual pharmacokinetic parameters for capecitabine were
estimated by standard noncompartmental analysis using WinNonlin
version 5.0 (Pharsight, Mountain View, CA) [27]. The capecitabine
data were fit to a one-compartment linear model using weighted least
squares regression. The pharmacokinetics of erlotinib was assessed by
compartments analysis using ADAPT II [28]. The erlotinib data were
fit to a one-compartment linear model using weighted least squares re-
gression and an iterative two-stage approach as previously described
[29]. For several patients, one or more blood samples were missed or
obtained improperly and were not usable for analysis. Any sample that
was documented not to be a pretreatment sample (i.e., within 3 hours
before the next dose or after a dose) was not used in subsequent anal-
ysis. After excluding concentrations from these samples, the total num-
ber of concentration-time observations per individual was relatively
small compared with the number of parameters estimated. Therefore,
an iterative two-stage approach was implemented to estimate pharma-
cokinetic parameters for all patients. Parameter estimates from single-
dose data from a previous trial conducted at our institution [29] were
used to establish Bayesian priors for the structural model parameters,
which included volume of the central compartment (Vc), absorption
rate constant (Ka), and elimination rate constant (Ke). An iterative
two-stage approach was used in each iteration updating the Bayesian
priors, until the mean estimates of all parameters differed by less than
5% from the previous mean estimate, which was our arbitrarily pre-
defined stopping point. In the final model fit, data from all patients,
including those with incomplete observations (four to six observations;
time of last plasma concentration = 8 to 24 hours), were analyzed using
a Bayesian algorithm to estimate individual structural parameters. Cal-
culated secondary pharmacokinetic parameters included half-life (T 1/2)
and apparent systemic clearance (Cls/F ). Area under the curve (AUC)
was calculated as dose divided by Cls/F. The maximum drug concen-
tration (Cmax) and time maximum plasma concentration achieved
(Tmax) values were obtained from the observed values for both erlotinib
and OSI-420.
Statistical Analysis
All outcome parameters were summarized using descriptive statis-
tics. AWilcoxon signed rank test was used to compare PK parameters
to erlotinib single-agent administration obtained from patients treated
on a previous clinical trial at our institution [29]. The a priori level of
significance was set at P < .05. These tests were performed using SPSS
version 15 (SPSS, Chicago, IL) or JMP Statistical Discovery software
(version 4.0.4; SAS Institute, Cary, NC).
Results
Patient Characteristics
Fourteen patients were enrolled to the study from March 2006 to
April 2008. Patients were observed for up to 8 weeks for toxicity on
completion of chemoradiation or removal from study. The character-
istics of the patients are shown in Table 2. Themedian age was 60 years
(range = 47–73 years) and 62% were females. Eight (85%) underwent
a pancreaticoduodenectomy, 4 (31%) underwent a distal pancreatec-
tomy, and 1 (8%) underwent a total pancreatectomy. After surgery, 10
had pathologic stage 2, 2 had stage 1, and 1 had stage 3 disease.
Toxicity of Chemoradiation and Determination of
Recommended Phase 2 Dose
Eight patients were enrolled to dose level 1. One patient was re-
placed after developing ischemic bowel from adhesions requiring
emergent surgery. A second patient had treatment-unrelated wound
dehiscence and was not evaluable for dose-limiting toxicity assessment.
This patient was replaced, although the toxicity data are reported here.
Four (57%) of the six evaluable patients completed the planned chemo-
radiation, although all required dose modification or interruption. Four
patients developed dose-limiting toxicities. The first patient experienced
grade 3 neutropenia for more than 5 days, and the second patient had
uncontrolled grade 3 diarrhea that required hospitalization. Both did
not complete the planned chemoradiation. The third patient developed
grade 3 sensory neuropathy requiring dose reduction, and the fourth
patient had grade 3 rash. Capecitabine dosing was interrupted in five
patients (range days 8-29) and erlotinib in three patients (range days
15-31). Dose level 1 was therefore determined as intolerable at a planned
interim analysis, and additional six patients were enrolled to dose level −1.
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All six patients enrolled to dose level −1 completed the planned che-
moradiation. Four patients developed elevated liver enzymes, which
improved when capecitabine and/or erlotinib were held for fewer than
7 days. All patients had grade 1 rash or worse and two had grade 1 diar-
rhea or worse. Dose level −1 was therefore considered clinically feasible
and declared as the recommended phase 2 dose. No grade 4 toxicity or
worse was observed at both dose levels. The most common (>30%)
grade 2 or worse treatment-related toxicities were fatigue (46%), ele-
vated alanine aminotransferase (46%), and anorexia (31%) (Table 3).
Chronic gastrointestinal toxicity was seen in two patients. One pa-
tient (dose level 1) developed a bile duct stricture at the surgical anasto-
mosis 1 year after theWhipple operation. A second patient (dose level −1)
developed radiation enteritis of the colon (within the radiation field)
27 months after a distal pancreatectomy. In an attempt to dilate the
stricture, the bowel was perforated, and the patient required surgery.
At the time of resection, the patient was found to have biopsy-proven
metastatic disease to the liver. No other late effects have been reported
from this cohort of patients.
Pharmacokinetic Evaluation
Erlotinib and capecitabine pharmacokinetic data was evaluable for
all patients. Erlotinib and OSI-420 Cmax, Tmax, AUC, and T 1/2 are
presented in Table 4. TheCmax of erlotinib was observed at 5.04 hours
after oral administration with a mean terminal half-life of 14.7 hours.
Erlotinib Cmax and AUC were comparable to data from an erlotinib
single-agent administration from another clinical trial at Johns Hopkins
(Figure 1) and published historical controls [29,30]. There was no
difference in the Cmax, Tmax, AUC, T 1/2 of capecitabine, 5′DFCR,
5′DFUR, and 5-FU with either dose of daily erlotinib (100 or
150 mg; P > .05). Therefore, the data are combined and presented
in Table 4. High interpatient variability was observed for capecitabine
and metabolite pharmacokinetic parameters, which is consistent with
previous reports in the literature [31–33].
Discussion
Concurrent chemoradiation preceding or followed by systemic chemo-
therapy remains one of the standards in the adjuvant treatment of
pancreatic cancer. The National Comprehensive Cancer Network rec-
ommends the use of fluoropyrimidines, including capecitabine, as a
radiosensitizer in the adjuvant setting [34]. The recent European Study
Group for Pancreatic Cancer 3 trial (ESPAC-3) study, randomizing re-
sected pancreatic cancer patients to gemcitabine or fluorouracil/folinic
acid, reported no significant survival difference between the two arms,
indicating that fluoropyrimidine may be as efficacious as gemcitabine
in the adjuvant setting [35]. Efforts to integrate EGFR inhibitors into
adjuvant therapy are of great interest after the positive result of erlotinib
in advanced disease. However, progress has been slowed by the lack of
a clinically feasible regimen.
At the inception of this protocol, there were limited preclinical studies
to guide how to optimally combine erlotinib, capecitabine, and radia-
tion [8,10]. Nevertheless, we hypothesized that combining an inhibitor
of the EGFR pathway (erlotinib) with capecitabine and radiation may
have a potent and selective antitumor activity against pancreatic cancer.
Czito et al. [19] evaluated concurrent conformal (three or four fields)
external-beam radiation therapy (50.4 Gy) with gefitinib 250 mg daily
and capecitabine twice daily (7 days/wk) at the doses of 650 and 825mg
in 10 pancreatic cancer patients. Six patients (60%) developed dose-
limiting toxicity, including diarrhea and arterial thrombi. The authors
concluded that the combination resulted in excessive toxicities, and the
recommended phase 2 dose was not determined. In comparison, the
starting dose level in our study (capecitabine 800 mg/m2, 7 days/wk)
also resulted in excessive toxicities, and the dose-limiting toxicity in-
cluded diarrhea, neutropenia, and rash. After dose de-escalation, the
combination of concurrent IMRTwith capecitabine 800 mg/m2 twice
daily (Monday to Friday) and erlotinib 100 mg daily resulted in less
toxicity and has been found to be clinically feasible and determined
to be the recommended phase 2 dose. We hypothesize that the lower
frequency of capecitabine (5 vs 7 days/wk) improved the tolerability
of this regimen. This coupled with the use of IMRT as opposed to
conformal irradiation may have resulted in less small bowel irradia-
tion, thus decreasing gastrointestinal toxicity. Although unclear,
reported anorexia was likely due to a combination of radiation and dif-
ficulty taking oral chemotherapy (erlotinib and capecitabine) after
surgical resection.
The toxicity profile of the study regimen is comparable to that previ-
ously known to be associated with the two agents given independently
or with radiation. In a study of capecitabine with concurrent radiation,
Dunst et al. [36] reported 825 mg/m2 twice a day on a continuous basis
with concurrent radiation as clinically feasible in rectal cancer. The dose-
limiting toxicity at 1000-mg/m2 twice-a-day level was hand-foot syn-
drome, and non–dose-limiting grade 3 toxicities or worse were diarrhea
and skin reactions. The recommended dose for capecitabine in our
study is comparable to that reported by Saif et al. [9,37], at the level
of 800 mg/m2 twice a day (Monday to Friday) with concurrent radi-
ation in locally advanced pancreatic cancer patients.
The frequency of non–dose-limiting liver enzyme elevation at the
recommended phase 2 dose in our study seems to be higher than pre-
viously published reports. In the National Cancer Institute of Canada
BR.21 trial, liver enzyme abnormalities were transient and occurred in
Table 3. Grade 2 and above Treatment-Related Toxicity during Chemoradiation.
Toxicity Toxicity Events by Dose Level
DL 1 (n = 7) DL −1 (n = 6)
Grade 2 Grade 3,4 Grade 2 Grade 3,4
Nonhematologic
Elevated ALT — — 5 1
Elevated AST — — 1 1
Elevated ALP — — 1 —
Hyperbilirubinemia — — 1 —
Abdominal pain — 1 — —
Diarrhea — 1* 1 —
Vomiting — 1 — —
Nausea 1 — — —
Dehydration 1 1 1 —
Rash — 2* 1 —
Mucositis 1 — — —
Dry skin — 1 1 —
Hand-foot syndrome 1 — — —
Anorexia 2 2 — —
Fatigue 5 — 1 —
Hyperglycemia 1 — 1 —
Insomnia 1 — — —
Ataxia 1 — — —
Neuropathy, sensory — 1 — —
Taste alteration 1 — — —
Infection 1 — — —
Hematologic
Neutropenia 2 1* — —
Lymphopenia — 6 1 4
Anemia 1 — — —
ALP indicates alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase.
*Dose-limiting toxicity.
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4% and less than 1% of erlotinib- and placebo-treated patients, respec-
tively [38,39]. There was no grade 3 or worse elevation in erlotinib-
treated patients. Saif et al. [9] reported grade 3 hyperbilirubinemia in
5% of pancreatic cancer patients who received concomitant radiation
with capecitabine 800mg/m2 twice a day (Monday to Friday) for 6weeks,
but there was no grade 3 or worse alanine aminotransferase, aspartate
aminotransferase, or alkaline phosphatase elevation. Liver enzyme
abnormalities were reported in less than 10% of patients receiving com-
binations containing capecitabine and erlotinib [32,33,40]. Our institu-
tional standard adjuvant therapy regimen (off protocol) is capecitabine
800 mg/m2 (Monday to Friday) with IMRT. These patients rarely
experience elevated liver function tests; therefore, we believe that this
elevation is more likely due to the addition of erlotinib. Given these,
we speculate that the higher frequency of liver enzyme elevation may
be a result of a longer continuous concurrent exposure to erlotinib
with capecitabine, and this should be monitored closely in future
adjuvant studies.
The recommended phase 2 dose of concurrent capecitabine and
erlotinib in our study is comparable to the efficacious dose in non–
radiation-containing regimens. Kulke et al. [40] reported a phase 2
study of a combination of erlotinib 150 mg daily continuously and
capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week
of rest in patients with gemcitabine-refractory metastatic pancreatic
cancer. The progression-free survival and median survival were com-
parable to published second-line studies at 3.4 and 6.5months, respec-
tively [41–44].
Drug-drug interaction was not expected between capecitabine and
erlotinib because their metabolic pathways are theoretically distinct.
In our study, the pharmacokinetic profile of erlotinib is not signifi-
cantly different in the presence of capecitabine when compared with an
erlotinib single-agent study [29]. This is consistent with previously
published trials of erlotinib in combination with capecitabine and
docetaxel or in combination with capecitabine and oxaliplatin [32,33].
High interpatient variability was observed for capecitabine and metab-
olite pharmacokinetic parameters, which is consistent with previous
literature, making it difficult to determine whether a drug-drug in-
teraction occurred [31–33]. In addition, there are conflicting data in
the literature regarding drug-drug interaction between erlotinib and
capecitabine. In a trial in breast cancer patients, no alterations in
capecitabine pharmacokinetics were noted when 825 mg/m2 twice a
day capecitabine was combined with erlotinib (100mg/d) and docetaxel
(60-75 mg/m2 intravenously every three weeks) [32]. However, there
Figure 1. Erlotinib Cmax (ng/ml) (A) and AUC (B) after a single dose of erlotinib and capecitabine (closed symbols) compared with erlotinib
alone (open symbols). Data for erlotinib alone were obtained from single-agent clinical trials at our institution.
Table 4. Summary of Pharmacokinetic Parameters for Erlotinib, Capecitabine, and Metabolites.
Dose Level Cmax (ng/ml) Tmax (hr) AUCinf (ng hr/ml) T 1/2 (hr)
Erlotinib
1 1033.4 ± 382.7 (8) 3.95 (1.83-25.00; 8) 28,385 ± 12,854 (4) 15.91 ± 2.16 (4)
2 592.7 ± 335.8 (6) 7.00 (4.00-8.08; 6) 14,872 ± 5000 (5) 13.80 ± 5.30 (5)
Both 5.04 (1.83-25.00; 14) 14.74 ± 4.13 (9)
OSI-420
1 80.1 ± 36.0 (8) 4.00 (1.83-25.00; 8) N.C. N.C.
2 41.7 ± 23.6 (6) 7.00 (4.00-8.08; 6) N.C. N.C.
Both 6.00 (1.83-25.00; 14) N.C. N.C.
Capecitabine
Both 4437.1 ± 3777.8 (14) 0.50 (0.25-3.48; 14) 4988.4 ± 2354.3 (11) 0.55 ± 0.24 (11)
5′DFCR
Both 3795.8 ± 1536.0 (14) 1.00 (0.42-4.97; 14) 7429.8 ± 1945.9 (13) 0.81 ± 0.21 (13)
5′DFUR
Both 4438.6 ± 2428.8 (14) 1.00 (0.42-3.97; 14) 6634.3 ± 2349.7 (13) 0.83 ± 0.26 (13)
5-FU
Both 337.1 ± 174.0 (14) 1.00 (0.42-3.97; 14) 555.3 ± 100.7 (7) 0.88 ± 0.44 (7)
Values are reported as the arithmetic mean ± SD (n). The Tmax is reported as the median (range).
AUCinf indicates area under the concentration-time curve from time 0 to infinity; Cmax, maximal plasma concentration; NC, not calculated; Tmax, time of the maximal plasma concentration; T 1/2, terminal
half-life.
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was a trend toward decreased capecitabine and metabolite exposure
when capecitabine (825-1000 mg/m2/d) was combined with erlotinib
(100mg/d) and oxaliplatin (130mg/m2 intravenously every three weeks)
in metastatic colorectal cancer patients [33]. In retrospect, monother-
apy and combination pharmacokinetic assessments should have been
performed in this trial to definitively confirm the presence or absence
of drug-drug interaction when involving a highly variable drug like
capecitabine. Regardless of the drug-drug interaction, in both trials
where capecitabine was combined with erlotinib, the maximum toler-
ated dose (MTD) of erlotinib was 100mg/d. This is consistent with the
MTD observed in the current trial. Whether a drug-drug interaction
exists and influences patient outcomes is unclear, and future studies
should incorporate appropriate pharmacokinetic studies to evaluate this
relationship definitively.
The role of erlotinib in combination with gemcitabine-containing
radiation regimens has been explored in pancreas cancer but in locally
advanced disease: Iannitti et al. [45] reported erlotinib 50 mg daily
as the MTD in combination with weekly gemcitabine (75 mg/m2),
paclitaxel (40 mg/m2), and radiation (50.4 Gy), whereas Duffy et al.
[46] reported erlotinib 100mg daily as theMTD in combination with
gemcitabine (40 mg/m2 twice weekly) and radiation 1.8 Gy daily. Re-
cently, the results fromESPAC-3 support the use of a fluoropyrimidine
in the adjuvant setting instead of gemcitabine, given the higher fre-
quency of hematological toxicities observed in the gemcitabine arm
[35]. The new intergroup adjuvant trial (Radiation Therapy Oncology
Group 0848) is evaluating six cycles of gemcitabine with or without
erlotinib followed by a randomization for patients to receive or not
to receive 5-FU–based chemoradiation. Unlike the regimen described
herein, the intergroup trial does not include erlotinib during the chemo-
radiation. As such, this trial is unique, as it is the first tolerable EGFR
inhibitor–containing adjuvant pancreas cancer regimen given concur-
rently with 5-FU–based chemoradiation.We are currently enrolling pa-
tients to the phase 2 cohort of the study, and we anticipate completion
within the next year.
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